High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study

Area of Science:

• Pediatric critical care
• Respiratory medicine
• Neonatalogy

Background:

• Bronchiolitis is a common respiratory infection in infants.
• Current management often involves supplemental oxygen, with potential for escalation to higher care levels.
• High-flow nasal cannula (HFNC) offers an alternative oxygen delivery method.

Purpose of the Study:

• To evaluate the safety and clinical impact of HFNC for infants with bronchiolitis on a general pediatric ward.
• To identify predictors of treatment response and non-response to HFNC.
• To assess the feasibility of a randomized controlled trial (RCT) for HFNC in bronchiolitis.

Main Methods:

• Prospective pilot study of 61 infants (<12 months) with bronchiolitis requiring oxygen.
• HFNC initiated at 2 L/kg/min, titrated to maintain oxygen saturation >94%.
• Comparison with a retrospective cohort (n=33) receiving standard low-flow oxygen.

Main Results:

• HFNC responders showed significant decreases in heart rate (HR) and respiratory rate (RR); non-responders did not.
• HFNC use was associated with a four-fold decreased likelihood of pediatric intensive care unit (PICU) admission (OR 4.086).
• No adverse events (e.g., pneumothorax, bradycardia, intubation) were observed with HFNC.

Conclusions:

• HFNC is a safe treatment modality for infants with bronchiolitis on a pediatric ward.
• Monitoring HR and RR within the first hour can identify non-responders likely to require PICU admission.
• This pilot study supports the design of an RCT to confirm HFNC's efficacy in reducing PICU admissions.